Description
Product Availability: In Stock (delivery within 2-3 business days, no extra charge for drop-shipping).
Ordering: To place an order via credit card or PO use Add to Cart button (creating an account is not required).
Transfection Reagent for NCI-H460 Cells (Lung Carcinoma Cells, HTB-177)
- Proprietary cationic lipids formulation
- High transfection efficiency of small RNA (siRNA, shRNA, miRNA), mRNA, pDNA
- Effective and robust intracellular delivery
- Kit includes Transfection Enhancer reagent
- Produces consistent results, lot-to-lot, plate-to-plate, and well-to-well
- Work in the presence of serum
- A proven reagent for establishing stable cell lines
- Optimized transfection protocols are adapted for use with both standard & reverse transfection methods
- Download in vitro NCIH460 transfection protocol: [PDF]
- Download NCI-H460 CRISPR/Cas9 transfection protocol: [PDF]
- Download PowerPoint presentation for NCI-H441 cells transfection kit: [PPT]
- Developed and manufactured by Altogen Biosystems
Transfection Efficiency:
Reagent exhibits at least 90% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems NCIH460 Transfection Protocol: [PDF]
Download MSDS: [PDF]
NCI-H460 Cell Line:
Lung cancer is considered one of the most lethal diseases with a low survival, high metastasis and recurrence rate. Although lung cancer treatment has dramatically improved within the last two decades, it is the primary cause of cancer deaths in both males and females globally. It results in approximately 158,000 fatalities in the United States annually, with more than half of the patients diagnosed at an advanced stage, as per the American Cancer Society. The NCI-H460 cell line was derived by A.F. Gazdar and colleagues in 1982 from a male with large cell lung carcinoma. This tumorigenic cell line exhibits epithelial morphology and has been known to express p53 mRNA as normal lung tissue does. The NCI-H460 cell line is also unique in the fact that it shows no significant structural DNA abnormalities. In addition to being negative for neurofilament triplet protein, NCI-H460 cells stain positively for vimentin and keratin. NCI-H46 is a hypotriploid cell line with the modal chromosome number of 57 that is essential for lung cancer research. Altogen Biosystems provides high efficiency lipid-based transfection reagent kits for the tumorigenic NCI-H460 lung cancer cell line.
Data:
Figure 1. Cyclophilin B silencing efficiency was determined by qRT-PCR in the NCI-460 cells transfected by Cyclophilin B siRNA or non-silencing siRNA control following the recommended transfection protocol. Cyclophilin mRNA expression levels were measured 48 hours post-transfection. 18S rRNA levels were used to normalize the Cyclophilin B data. Values are normalized to untreated sample. Data are presented as means ± SD (n=6).
Figure 2. Protein expression Cyclophilin B in NCI-H460 cells. DNA plasmid expressing Cyclophilin B or siRNA targeting Cyclophilin B were transfected into NCI-H460 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Selected in vivo transfection product citations (ALTOGEN® IN VIVO Transfection Kits used in the following publications):
- Nature. 2008 454(7203):523-7. Innate immunity induced by composition-dependent RIG-I …Saito et al [PDF]
- Am J Pathology. 2010 177(4):1870-80. Role of ocular complement factor H in a murine model … Lyzogubov et al [PDF]
- Nature Biotechnology. 2011 29(4):341-5. Delivery of siRNA to the mouse brain by … Alvarez-Erviti et al [PDF]
- Cancer Research. 2011 71(15):5144-53. Inhibition of miR-193a expression by… Iliopoulos et al [PDF]
- RNA. 2010 16(11):2108-19. RNase L releases a small RNA from HCV RNA that refolds … Malathi et al [PDF]
- Diabetologia. 2012 55(7):2069-79. The p47phox- and NADPH oxidase organiser 1 … Youn et al [PDF]
- British Journal of Cancer. 2012 107(3):516-26. TIGAR induces p53-mediated cell-cycle … Madan et al [PDF]
- Hypertension. 2014 63(2):353-61. Tissue transglutaminase contributes to … Liu et al [PDF]
- Circulation Research. 2010 15;107(8). Kruppel-like factor-4 transcriptionally regulates … Cowan et al [PDF]
- Hypertension. 2012 59(1):158-66. Role of uncoupled endothelial nitric oxide synthase … Gao et al [PDF]
- Jounal of Biological Chemistry. 2012 287(4):2907. Chaperoning of mutant p53 protein … Gogna et al [PDF]
- PLoS Pathogens. 2012 8(8) Uridine composition of the poly-U/UC tract of HCV RNA … Schnell et al [PDF]
- J Proteome Res. 2012(11) Retinal proteome analysis in a mouse model of oxygen-induced … Kim et al [PDF]
- Gastroenterology. 2011 141(2) Differential type I interferon-mediated autophagic trafficking … Desai et al [PDF]
- PLoS Pathog. 2014 10(10) Exosomes from hepatitis C infected patients transmit HCV … Bukong et al [PDF]
NCI-H460 Transfection Kit
Altogen Biosystems:
Altogen Biosystems manufacturers preoptimized transfection kits for cancer research. Reagents and transfection protocols are optimized for individual cancer cell lines. Altogen Biosystems developed two types of in vivo delivery kits for animal research: Tissue-targeted reagents (delivery into liver, pancreas, and kidney tissues), and in vivo biodistribution reagents (PEG-Liposome, Nanoparticle, Lipid, and Polymer-based kits). Optimized transfection protocols provide efficient intracellular delivery of proteins, DNA, and RNA molecules in vitro and in vivo. Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Research Services:
Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
Volume Options:
- 0.5 ml (Catalog #6864)
- 1.5 ml (Catalog #6865)
- 1.5 ml CRISPR (Catalog #2182)
- 8.0 ml (Catalog #7071)
AltogenBiosystems是一家开发和制造用于生命科学研究,药物发现和开发的转染试剂盒的生物技术公司。转染试剂盒针对特定癌细胞系和原代细胞培养进行了优化,可将生物分子有效递送到靶组织中。通过先进的试剂配方和优化的转染方案实现体外(癌细胞系)和体内(动物组织靶向试剂、癌细胞系)递送货物分子,包括质粒DNA,各种类型的RNA(mRNA,siRNA,shRNA,microRNA),蛋白质和小分子研究。
Altogen生命科学公司致力于研发,生产和销售特定细胞系的转染试剂,用于细胞间生物分子的传递,并通过对转染试剂类型的设计将siRNA和质粒DNA有效地转入不同的细胞系和原代细胞内。Altogen公司开发的聚合物,脂质体,纳米粒子为基础的转染技术分别针对分子生物学,组合化学,和细胞生物学而分别应用。Altogen定制服务提供符合GLP要求定制研究服务,包括代稳定的细胞系,细胞银行和冷冻保存,焦磷酸测序,克隆,RNA干扰(RNAi)和基因沉默服务,发展分析,siRNA文库筛选,并转染服务。稳定的肿瘤细胞株和原代细胞的产生,可以是非常昂贵和费时。该公司的细胞培养科学家的细胞株的选择,无论是利息或shRNA表达载体的稳定表达的基因改造。标准的RNAi技术服务,包括设计与合成的siRNA的利益,验证siRNA的沉默效率,siRNA转染条件的优化,使高效的基因沉默细胞系或原代培养细胞的靶基因。转染培养细胞的瞬时或稳定的引入外源性分子和遗传物质(即RNA或DNA),通常是在生物实验室用来研究基因功能,基因表达的调节,生化映射,突变分析,和蛋白质的生产。科学家利用各种载体分子,这种分子,使质粒DNA(PDNA),信使RNA(mRNA),短干扰RNA(siRNA),小分子RNA(miRNA)的,并进入肿瘤细胞株和原代细胞的蛋白质的基因交付。不幸的是,无单提货的方法或转染试剂,可以适用于所有类型的细胞,细胞的细胞毒性和转染效率显着不同,取决于试剂,协议,并正在利用细胞类型。Altogen生物系统公司提供超过60种类型的细胞的预优化转染试剂盒。纳米粒子,脂质和聚合物基ALTOGEN®在体内转染试剂,使交付功能的RNA和DNA分子在体内。PEG脂质体在体内输送系统减少由于PEG修饰的先天免疫反应,并提供高效的siRNA转染的DNA,并在体内的蛋白质。由科学“杂志(2010年12月17日):PEG脂质体在体内转染试剂盒siRNA的特色Altogen生物系统功能的特定细胞系转染试剂盒
120+细胞转染试剂和活体组织靶向试剂盒制造商AltogenBiosystems是一家生物技术公司,开发和制造用于生命科学研究、药物发现和开发的转染试剂盒。Altogen®体内转染试剂可有效地将生物分子导入靶组织。细胞转染试剂盒针对特定的癌细胞系和原代细胞进行了优化。通过先进的试剂配方和优化的转染方案实现货物分子(DNA、RNA、蛋白质)的高效传递。AltogenBiosystems利用高分子化学、分子和细胞生物学的专业知识,开发了新的体内外给药技术。转染是将外源分子导入培养细胞中,常用于研究基因功能、基因表达调控、生化定位和蛋白质生产。不幸的是,由于细胞毒性和转染效率的差异很大,并且取决于所使用的试剂、方案和细胞类型,因此没有一种单一的传递方法或转染试剂可应用于所有类型的细胞。AltogenBiosystems为120多个癌细胞系和原代细胞类型提供优化的转染试剂盒和电穿孔产品。体内转染试剂可实现组织靶向给药。Altogen的转染试剂盒包括用于体外(癌细胞系)和体内(用于动物研究的组织靶向试剂)转染的转染增强剂试剂和转染复合物冷凝器。Altogen实验室提供符合GLP的实验室合同研究服务。我们的生物CRO服务包括异种移植物的疗效、IND应用的pharm/tox研究和安全性测试、分析开发(ELISA、IC-50、qPCR)、90多个异种移植物动物模型、RNAi和基因沉默服务。Altogen的细胞培养科学家通过在28天内培育出稳定的细胞系,将选择的细胞系转化为稳定表达感兴趣的基因。
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
质粒转染一般是说DNA转染,用常用的sinofection等转染试剂就可以;
小干扰RNA(Small interfering RNA;siRNA)有时称为短干扰RNA(short interfering RNA)或沉默RNA(silencing RNA),是一个长20到25个核苷酸的双股RNA,这种RNA的转染需要用专门的RNA转染试剂。
如题,PolyplusTransfection转染试剂在中国区的代理商有哪些?求推荐1-2个靠谱的,谢谢!
想用RNAiMAX或者lipo2000转染siRNA,但是看了下转染试剂的说明书和锐博的siRNA说明书,觉得分别对siRNA的用量描述差别挺大的呀,不知道到底该参考哪个呢。
以24孔板为例在siRNA说明书中写到,siRNA终浓度是50nM的话,加入浓度为20μM的siRNA1.25ul,每孔体积是500ul,那这样的话,每孔最终siRNA的量是25pmol。
但是在RNAiMAX或者是lipo2000说明书中,一个写的每孔siRNA用量是5pmol,一个是500ng,这与siRNA厂家所提供的量相差也太多了吧。
到底该看哪一个呢。
ps.一旦siRNA的量和体积确定下来之后,转染试剂的量和siRNA1:1的加就可以了吗?
请各位大神解答。
1.siRNA说明书中的用量,红线圈出
2.RNAIMAX说明书中siRNA的用量。
3.lipo2000说明书中siRNA用量
对重复性要求不高的试验,一般没有问题的,只不过可能需要增加一些转染试剂用量了。
为了避免这个问题,推荐收到货之后,进行适当分装,用多少,拿出来多少最好。
但是在选择的时候,也需要注意其他的一些问题。
1、采用何种原料和抗体,是否高效、灵敏、特异
2、规范包被操作,吸附是否均匀
3、重复性、可靠性
6、是否提供技术服务
7、适用于血浆、血清、组织匀浆液、细胞培养上清液、尿液等多种类型的样本
8、可检测动物类型是否丰富
9、可检测指标是否齐全
elisa试剂盒就查下博欧特生物
使用方法:
1、 血清:操作过程中避免任何细胞刺激。使用不含热原和内毒素的试管。收集血液后,1000×g离心10分钟将血红细胞迅速小心地分离。
2、 血浆:EDTA、柠檬酸盐、肝素血浆可用于检测。1000×g离心30分钟去除颗粒。
3、 细胞上清液:1000×g离心10分钟去除颗粒和聚合物。
4、 组织匀浆:将组织加入适量生理盐水捣碎。1000×g离心10分钟,取上清液。
5、 保存:如果样品不立即使用,应将其分成小部分-70℃保存,避免反复冷冻。尽可能的不要使用溶血或高血脂血。如果血清中大量颗粒,检测前先离心或过滤。不要在37℃或更高的温度加热解冻。应在室温下解冻并确保样品均匀地充分解冻。
内毒素是革兰氏阴性菌细胞壁(cellwall)上的特有成分,主要是脂多糖中的类脂A,在细菌被裂解时被释放出来,由于其化学结构和特性,在质粒的纯化过程中很容易混入质粒DNA一同提取出来。内毒素的存在会严重的影响质粒转染细胞的效率,此外会激活造血细胞(如B细胞、巨噬细胞等)的非特异免疫反应,造成实验的假阳性,所以转染级质粒的提取纯化必须去除内毒素。